SERPIND1

Heparin cofactor 2 • UniProt accession P05546

Thrombin inhibitor activated by the glycosaminoglycans, heparin or dermatan sulfate. In the presence of the latter, HC-II becomes the predominant thrombin inhibitor in place of antithrombin III (AT-III). Also inhibits chymotrypsin, but in a glycosaminoglycan-independent manner

Source: UniProt

Expressed predominantly in liver. Also present in plasma

Expressed in plasma (at protein level) (PubMed:32827448). Expressed in liver (PubMed:32827448)

Source: UniProt

The N-terminal acidic repeat region mediates, in part, the glycosaminoglycan-accelerated thrombin inhibition

Source: UniProt
  • Thrombophilia due to heparin cofactor 2 deficiency (THPH10)

    A hemostatic disorder characterized by a tendency to recurrent thrombosis.

Source: UniProt
  • Intrinsic Pathway of Fibrin Clot Formation
  • Common Pathway of Fibrin Clot Formation
  • Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs)
  • Post-translational protein phosphorylation
Source: Reactome via UniProt

Mutations

No mutation information available.

Synthetic Lethal Network

Genes with an experimentally identified or computationally predicted synthetic-lethal relationship to SERPIND1, aggregated across our SSL data sources. Click any partner node to view that gene’s page.

Nodes and edges are coloured by the SSL data source. Partners appearing in more than one source are shown in grey.

BioGRID SLOrth SynLethDB MexDrugs Multi-source
Sources: BioGRID, SLOrth, SynLethDB, MexDrugs

Clinical Trials

Total Trials Found: 1

NCT ID Condition Brief Title Phase Status
NCT03203421 Malaria A Safety and Efficacy Study of ChAdOx1 LS2 and MVA LS2 PHASE1, PHASE2 COMPLETED